A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
type: MedicalStudy
description: A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE1
start date: 2015-09-02
end date: 2023-05-09
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT02509039
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Celgene
study subject: Lymphoma, Non-Hodgkin
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Lymphoma, Non-Hodgkin

AI Analytics
type: Organization